Matches in SemOpenAlex for { <https://semopenalex.org/work/W2807732548> ?p ?o ?g. }
- W2807732548 endingPage "2540" @default.
- W2807732548 startingPage "2532" @default.
- W2807732548 abstract "Aims Dapagliflozin is a selective inhibitor of sodium glucose co-transporter 2 (SGLT2). This study assessed the efficacy and safety of dapagliflozin 10 mg vs placebo in patients with type 2 diabetes (T2D) and moderate renal impairment (estimated glomerular filtration rate [eGFR], 45–59 mL/min/1.73 m2; chronic kidney disease [CKD] stage 3A). Materials and methods In this double-blind, parallel group, Phase 3 study (NCT02413398, clinicaltrials.gov) patients with inadequately controlled T2D (HbA1c 7.0%-11.0%) were randomized (1:1) to dapagliflozin 10 mg once daily (N = 160) or matching placebo (N = 161) for 24 weeks. Randomization was stratified by pre-enrolment glucose-lowering therapy. The primary endpoint was change from baseline in HbA1c at Week 24. Results At Week 24, compared with placebo, dapagliflozin significantly decreased HbA1c (difference [95% CI], −0.34% [−0.53, −0.15]; P < 0.001), body weight (difference [95% CI], −1.25 kg [−1.90, −0.59]; P < 0.001), fasting plasma glucose (difference [95% CI], −0.9 mmol/L [−1.5, −0.4]; P = 0.001) and systolic blood pressure (difference [95% CI], −3.1 mm Hg [−6.3, 0.0]; P < 0.05). Decreases from baseline in eGFR were greater with dapagliflozin than placebo at Week 24 (−2.49 mL/min/1.73 m2 [−4.96, −0.02]), however, eGFR returned to baseline levels at Week 27 (3 weeks post-treatment) (0.61 mL/min/1.73 m2 [−1.59, 2.81]). No increase in adverse events (AEs; 41.9% vs 47.8%) or serious AEs (5.6% vs 8.7%) were reported with dapagliflozin versus placebo. No AEs of bone fractures, amputations or DKA were reported. Conclusions The findings of this study (NCT02413398, clinicaltrials.gov) support the positive benefit/risk profile of dapagliflozin for the treatment of patients with T2D and CKD 3A." @default.
- W2807732548 created "2018-06-21" @default.
- W2807732548 creator A5011703939 @default.
- W2807732548 creator A5012551917 @default.
- W2807732548 creator A5034383160 @default.
- W2807732548 creator A5037748733 @default.
- W2807732548 creator A5039307237 @default.
- W2807732548 creator A5040182038 @default.
- W2807732548 creator A5041913215 @default.
- W2807732548 creator A5064872622 @default.
- W2807732548 creator A5066210400 @default.
- W2807732548 date "2018-07-10" @default.
- W2807732548 modified "2023-10-17" @default.
- W2807732548 title "Efficacy and safety of dapagliflozin in patients with type 2 diabetes and moderate renal impairment (chronic kidney disease stage 3A): The DERIVE Study" @default.
- W2807732548 cites W1503352903 @default.
- W2807732548 cites W1973240292 @default.
- W2807732548 cites W2008687581 @default.
- W2807732548 cites W2019285763 @default.
- W2807732548 cites W2023984564 @default.
- W2807732548 cites W2030192134 @default.
- W2807732548 cites W2057656858 @default.
- W2807732548 cites W2077038286 @default.
- W2807732548 cites W2091059844 @default.
- W2807732548 cites W2093935121 @default.
- W2807732548 cites W2110344696 @default.
- W2807732548 cites W2122077393 @default.
- W2807732548 cites W2122808146 @default.
- W2807732548 cites W2127833912 @default.
- W2807732548 cites W2131355263 @default.
- W2807732548 cites W2146105386 @default.
- W2807732548 cites W2146264128 @default.
- W2807732548 cites W2150855258 @default.
- W2807732548 cites W2152413054 @default.
- W2807732548 cites W2187514862 @default.
- W2807732548 cites W2424539745 @default.
- W2807732548 cites W2436309489 @default.
- W2807732548 cites W2500767839 @default.
- W2807732548 cites W2595201361 @default.
- W2807732548 cites W2614137535 @default.
- W2807732548 cites W2626446274 @default.
- W2807732548 cites W2756910166 @default.
- W2807732548 cites W2782920834 @default.
- W2807732548 cites W2793355388 @default.
- W2807732548 cites W2904387867 @default.
- W2807732548 doi "https://doi.org/10.1111/dom.13413" @default.
- W2807732548 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/6175614" @default.
- W2807732548 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/29888547" @default.
- W2807732548 hasPublicationYear "2018" @default.
- W2807732548 type Work @default.
- W2807732548 sameAs 2807732548 @default.
- W2807732548 citedByCount "119" @default.
- W2807732548 countsByYear W28077325482017 @default.
- W2807732548 countsByYear W28077325482018 @default.
- W2807732548 countsByYear W28077325482019 @default.
- W2807732548 countsByYear W28077325482020 @default.
- W2807732548 countsByYear W28077325482021 @default.
- W2807732548 countsByYear W28077325482022 @default.
- W2807732548 countsByYear W28077325482023 @default.
- W2807732548 crossrefType "journal-article" @default.
- W2807732548 hasAuthorship W2807732548A5011703939 @default.
- W2807732548 hasAuthorship W2807732548A5012551917 @default.
- W2807732548 hasAuthorship W2807732548A5034383160 @default.
- W2807732548 hasAuthorship W2807732548A5037748733 @default.
- W2807732548 hasAuthorship W2807732548A5039307237 @default.
- W2807732548 hasAuthorship W2807732548A5040182038 @default.
- W2807732548 hasAuthorship W2807732548A5041913215 @default.
- W2807732548 hasAuthorship W2807732548A5064872622 @default.
- W2807732548 hasAuthorship W2807732548A5066210400 @default.
- W2807732548 hasBestOaLocation W28077325481 @default.
- W2807732548 hasConcept C126322002 @default.
- W2807732548 hasConcept C126894567 @default.
- W2807732548 hasConcept C134018914 @default.
- W2807732548 hasConcept C142724271 @default.
- W2807732548 hasConcept C159641895 @default.
- W2807732548 hasConcept C168563851 @default.
- W2807732548 hasConcept C197934379 @default.
- W2807732548 hasConcept C203092338 @default.
- W2807732548 hasConcept C204243189 @default.
- W2807732548 hasConcept C204787440 @default.
- W2807732548 hasConcept C27081682 @default.
- W2807732548 hasConcept C2777180221 @default.
- W2807732548 hasConcept C2777422806 @default.
- W2807732548 hasConcept C2778653478 @default.
- W2807732548 hasConcept C555293320 @default.
- W2807732548 hasConcept C71924100 @default.
- W2807732548 hasConcept C90924648 @default.
- W2807732548 hasConceptScore W2807732548C126322002 @default.
- W2807732548 hasConceptScore W2807732548C126894567 @default.
- W2807732548 hasConceptScore W2807732548C134018914 @default.
- W2807732548 hasConceptScore W2807732548C142724271 @default.
- W2807732548 hasConceptScore W2807732548C159641895 @default.
- W2807732548 hasConceptScore W2807732548C168563851 @default.
- W2807732548 hasConceptScore W2807732548C197934379 @default.
- W2807732548 hasConceptScore W2807732548C203092338 @default.
- W2807732548 hasConceptScore W2807732548C204243189 @default.
- W2807732548 hasConceptScore W2807732548C204787440 @default.
- W2807732548 hasConceptScore W2807732548C27081682 @default.
- W2807732548 hasConceptScore W2807732548C2777180221 @default.